Revista de esclerosis múltiple

Comentario breve

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Comentario breve

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Comentario breve

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Comentario breve

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Comentario breve

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Perspectiva

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Perspectiva

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Mini revisión

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Mini revisión

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspectiva

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Perspectiva

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Mini revisión

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspectiva

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Mini revisión

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Mini revisión

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspectiva

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspectiva

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspectiva

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspectiva

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspectiva

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Artículo de investigación

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Artículo de investigación

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Artículo de investigación

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Artículo de investigación

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Volumen 11, Asunto 1 (2024)

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Puntos destacados de la revista

indexado en